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Abstract
Background: Obesity-related adipose inflammation has been thought to be a causal factor for the development of insulin
resistance and type 2 diabetes. Infiltrated macrophages in adipose tissue of obese animals and humans are an important
source for inflammatory cytokines. Clodronate liposomes can ablate macrophages by inducing apoptosis. In this study, we
aim to determine whether peritoneal injection of clodronate liposomes has any beneficial effect on systemic glucose
homeostasis/insulin sensitivity and whether macrophage content in visceral adipose tissue will be reduced in diet-induced
obese (DIO) mice.
Methodology/Principal Findings: Clodronate liposomes were used to deplete macrophages in lean and DIO mice.
Macrophage content in visceral adipose tissue, metabolic parameters, glucose and insulin tolerance, adipose and liver
histology, adipokine and cytokine production were examined. Hyperinsulinemic-euglycemic clamp study was also
performed to assess systemic insulin sensitivity. Peritoneal injection of clodronate liposomes significantly reduced blood
glucose and insulin levels in DIO mice. Systemic glucose tolerance and insulin sensitivity were mildly improved in both lean
and DIO mice treated with clodronate liposomes by intraperitoneal (ip) injection. Hepatosteatosis was dramatically
alleviated and suppression of hepatic glucose output was markedly increased in DIO mice treated with clodronate
liposomes. Macrophage content in visceral adipose tissue of DIO mice was effectively decreased without affecting
subcutaneous adipose tissue. Interestingly, levels of insulin sensitizing hormone adiponectin, including the high molecular
weight form, were significantly elevated in circulation.
Conclusions/Significance: Intraperitoneal injection of clodronate liposomes reduces visceral adipose tissue macrophages,
improves systemic glucose homeostasis and insulin sensitivity in DIO mice, which can be partially attributable to increased
adiponectin levels.
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Introduction
Obesity has become a huge public health burden since it is
related to the development of many chronic diseases such as type 2
diabetes. Elevated inflammatory markers in circulation have been
commonly observed in obese and diabetic patients [1–5]. Inflamed
adipose tissue and circulating mononuclear cells are possible
sources for releasing increased inflammatory markers [6,7].
Recently, extensive studies have been performed to determine
the role of adipose inflammation in development of obesity-related
insulin resistance and type 2 diabetes [8–11]. Animal models have
shown strong evidence that adipose tissue originated low degree
inflammation may play a role for inducing systemic insulin
resistance in obese state. Multiple types of immune cells have been
identified in obese adipose tissue, such as macrophages, neutro-
phils, T cells and mast cells [6,12–16]. Macrophages accumulated
and activated in adipose tissue in obesity have been shown to
secrete a variety of proinflammatory cytokines, which potentially
contribute to obesity-related chronic inflammation [6,17]. Polar-
ization of macrophages from anti-inflammatory M2 state to
proinflammatory M1 state is thought to be the mechanism of
macrophage activation induced by high fat diet [18]. Diet induced
obese mice with reduced adipose macrophage infiltration have
improved insulin sensitivity, as observed in mice deficient in
CCR2, osteopontin and CXCL14 [19–21]. Proinflammatory
macrophages accumulated in obese adipose tissue express
CD11c and conditional depletion of CD11c positive cells through
genetic approach also restores insulin sensitivity [22]. Consistently,
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mice with increased adipose tissue macrophage accumulation have
compromised insulin sensitivity, as shown in cbl-b deficient and
MCP-1 transgenic mice [23–25].
Ablation of adipose tissue macrophage content will be
important to evaluate the therapeutic feasibility for improving
obesity-related insulin resistance. The genetic approach that was
used to deplete adipose tissue CD11c+ macrophages implied bone
marrow transplant to introduce CD11c-diphtheria toxin receptor
(DTR) bone marrow into lethally irradiated wild type mice and
followed by injection of diphtheria toxin. This approach not only
depletes CD11c+macrophages in adipose tissue, it is also expected
to deplete macrophages in other tissues such as lung [26]. In
addition, CD11c is not a macrophage specific marker, transgenic
expression of DTR-EGFP under a cd11c promoter also resulted in
deletion of dendritic cells, activated CD8+ T cells and plasma B
cells [26]. Clodronate liposomes have been widely used to
specifically ablate macrophages in many tissues through inducing
macrophage apoptosis. Intravenous injection of clodronate
liposomes is sufficient for depletion of macrophages in liver and
spleen but was insufficient for reaching other organ/tissue in
peritoneal cavity [27,28]. Clodronate liposomes can not penetrate
vascular barriers so local injections have been applied for
eliminating macrophages in most of the tissues such as pancreas,
lung, lymph nodes, testis, joints and central nervous system. We
successfully reduced macrophage content in visceral adipose tissue
of DIO mice by intraperitoneal injection (i.p.) of clodronate
liposomes. Two previous studies applied a small amount of
clodronate liposomes to DIO mice (approximately 4–5 mg/kg)
which was not expected to have an effect on visceral adipose
macrophage content and conflicting results were reported on
hepatosteatosis [29,30]. A third report with unspecified amount of
clodronate liposomes administered into DIO mice did not
investigate the effect on glucose homeostasis/systemic insulin
sensitivity or macrophage content in adipose tissue [31].
Therefore, our work provides novel information regarding the
beneficial effect of clodronate liposomes on glucose homeostasis
which is associated with reduction of macrophage content in
visceral but not subcutaneous adipose tissue [30,31].
Methods
Ethics statement
Animal experiments were approved by the Institutional Animal
Care and Use Committee of Rhode Island Hospital (protocol
0293-07 and de novo renew 0161-10).
Reagents
Clodronate liposomes were purchased from clodronatelipo-
somes.org (Vrije Universiteit, Netherlands) at the concentration of
1 mg/ml and prepared as previously described [32]. Clodronate
was a gift of Roche Diagnostics GmbH, Mannheim, Germany.
Adiponectin ELISA kits were purchased from R&D Systems. High
molecular weight mouse adiponectin ELISA kit was purchased
from BioVendor. IL-6 and TNFa ELISA kits were purchased
from BioLegend. Leptin ELISA kit was purchased from
RayBiotech. F4/80 antibody was purchased from Serotec. ATP,
horse radish peroxidase, glycerol phosphate oxidase, glycerol
kinase and lipase were purchased from Sigma. Amplex red was
purchased from Molecular Probes. Humulin R was purchased
from Eli Lilly Inc.
Histology
Epididymal, mesenteric, peri-nephric adipose tissue, and liver
were harvested from mice and weighted. For adipose tissue, one
portion was used to isolate primary adipocytes and stromal
vascular cells; one portion was frozen in liquid nitrogen
immediately and stored at 280uC; and one portion was fixed in
10% formalin for one day, then transferred to 70% ethanol and
paraffin embedded. For liver, one portion was fixed in 10%
formalin for histology and the rest was frozen in liquid nitrogen
immediately and stored at 280uC. Hematoxylin-eosin staining
and F4/80 immunohistochemistry were done in Rhode Island
Hospital core laboratory. F4/80 antibody was used at a 1:50
dilution. Slides were counterstained with methyl green. To count
macrophages, slides were viewed with a Nikon E800 microscope,
using a 40x PlanApo objective. Cells stained for F4/80 were
visually counted and recorded. Eight randomly selected views were
counted per slide.
Isolation of primary adipocytes and stromal vascular cells
Epididymal and mesenteric fat pads from DIO mice were
excised, weighted, and rinsed in isolation buffer. Fat pads were
then cut into small pieces in isolation buffer. Type I collegenase
was added at a final concentration of 1 mg/ml. Minced fat pads
were digested at 37uC in a shaking water bath at 100 rpm for 30
minutes. Digested tissues were then filtered through a metal mesh
with a pore size of 380 mM to get single cell suspension. Cell
suspensions were centrifuged at 1000 rpm for 3 min at room
temperature. Floating adipocytes were transferred to clean tubes
and rinsed twice with isolation buffer. The pellets, which contain
stromal vascular cells, were resuspended in red blood cell lysis
buffer to remove red blood cells. Next, stromal vascular cells were
rinsed in PBS and filtered through a metal mesh with a pore size of
94 mM to get single cells.
Tissue triglyceride measurement
Tissues were weighed and homogenized for 40 seconds in 30
volumes of ethanol. Samples were then vortexed for 5 minutes and
settled for 5 minutes at room remperature. One milliliter of
supernatant was transferred to a clean 1.5 ml tube and centrifuged
at 15,000 g for 10 minutes at room temperature. For measuring
triglyceride, five microliters of triglyceride standards or samples
were mixed with one hundred microliters of reaction buffer
(100 mM Tris, pH 7.4, 1 mM MgCl2 0.05 mM ATP, 0.2 U/ml
horse radish peroxidase, 1 U/ml glycerol phosphate oxidase, 2 U/
ml glycerol kinase, 25 U/ml lipase, and 0.05 mM amplex red) and
incubated for thirty minutes at 37uC. The fluorescence was read at
excitation 530 nM/emission 590 nM using Synergy 4 plate reader
(BioTek Instruments, Inc.).
RNA extraction and real-time PCR analysis
RNA samples were extracted from tissues or isolated cells using
the TRIzol reagent (Invitrogen, Carlsbad, CA) or the RNAeasy kit
(Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. DNase I-treated RNA samples were reverse-transcribed with
SuperScript III reverse transcriptase (Applied Biosystems, Carls-
bad, CA) and random hexamers (Invitrogen, Carlsbad, CA) to
generate cDNA. Real-time PCR analysis was performed using
Power SYBR Green RT-PCR Reagent (Applied Biosystems,
Carlsbad, CA) on ABI Prism thermal cycler model StepOnePlus
(Applied Biosystems, Carlsbad, CA). Each 15-ml PCR reactions
contained 16 reaction mix, 5.5 mM MgSO4, 300 nM forward
primer, 300 nM reverse primer. The thermal cycling program was
50uC for 2 minutes, followed by 95uC for 10 minutes for 1 cycle,
then 95uC for 15 seconds, followed by 60uC for 1 minute for 40
cycles. Melting curve analysis was performed to ensure the
specificity of primers. Beta-actin was used as a reference gene in
each reaction.
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Mouse models
Male C57BL/6J mice were purchased from the Jackson
Laboratory at the age of 3 weeks. After one week of acclimation,
mice were fed on either a normal chow diet (5% kcal from fat) or a
high-fat diet (60% kcal from fat, D12492, Research Diets). Mice
were injected with approximately 110 mg/kg of clodronate
liposomes i.p. or equal volume of PBS liposomes. The injection
was repeated three days later and experiments were performed 6–7
days after the first injection. For insulin tolerance tests, 22.1-week
old DIO mice with 18.1-week on high fat diet and 25-week old lean
mice were used for injection of clodronate liposomes. Mice were
fasted for 6 hours and injected with insulin at the dose of 1 U/kg for
DIO mice and 0.5 U/kg for lean mice. Blood glucose levels were
measured using the AlphaTRAK blood glucometer (Abbott Animal
Health) every 15 minutes up to 90 minutes. For glucose tolerance
tests, 22.4-week old DIO mice with 18.4-week on high fat diet and
25-week old lean mice were used for injection of clodronate
liposomes. Mice were fasted overnight and then injected with
glucose at the dose of 1 g/kg for DIO mice and 2 g/kg for lean
mice. Blood glucose levels were measured every 15 minutes up to 90
minutes. Tissues were harvested 1–2 days after GTT experiments.
For insulin signaling studies, 24.6-week old DIO mice with 20.6-
week on high fat diet were used for injection of clodronate
liposomes. Insulin was injected into DIO mice through portal vein
at the dose of 0.75 U/kg. Five minutes post insulin injection, tissues
were collected and immediately frozen in liquid nitrogen. For
intravenous injection of clodronate liposomes, 22.5 week old DIO
mice with 18.5-week on high fat diet were used.
Hyperinsulinemic-euglycemic clamp study
Mice were cannulated through jugular vein seven to ten days
prior to experiments. DIO mice fed on a high fat diet for 25–29.5
weeks were used for injection of clodronate liposomes post surgery.
The day before experiments, mice were fasted overnight. Next day
mice were infused with HPLC purified D-[3-3H]-glucose (Perkin
Elmer) at the rate of 0.05 mCi/min during a 2 h basal period. Blood
glucose levels were measured at 60 and 120 minutes and blood
samples were collected at the end of basal period. After the basal
period, a bolus of human insulin (Humulin R) was infused for 3 min
(16 mU/kg), which equals to the entire amount of insulin used in a
two hour clamp. A 120-min hyperinsulinemic-euglycemic clamp
was then performed through infusion of D-[3-3H]-glucose at the
rate of 0.1 mCi/min plus continuous infusion of human insulin at
the rate of 2.5 mU/kg/min. A solution of 25% dextrose was infused
at variable rates to maintain blood glucose concentrations at basal
levels. Infusions were performed using microdialysis pump (CMA/
Microdialysis). Blood glucose levels were measured every 10
minutes. To estimate insulin-stimulated glucose uptake in individual
tissues, 2-deoxy-D-[1-14C]-glucose (Perkin Elmer) was administered
as a bolus of 10 mCi 75 minutes after the start of clamp. Blood
samples were taken at 80, 85, 90, 100, 110, and 120 minutes during
the clamp period for determining plasma concentrations of
3H-glucose, 3H2O, and 2-deoxy-D-[1-
14C]-glucose. At the end of
clamp, mice were sacrificed for collecting gastronemius muscles and
epididymal fat tissue. Each tissue was frozen immediately in liquid
nitrogen and stored at 280uC for further analysis. For determina-
tion of plasma concentrations of 3H-glucose and 2-deoxy-D-
[1-14C]-glucose, plasma samples were deproteinized with Ba(OH)2
and ZnSO4, dried to remove
3H2O, resuspended in water, and
counted in scintillation fluid (EcoLume) on channels for 3H and 14C.
The plasma concentrations of 3H2O were determined by the
difference between 3H counts without and with drying. For
determination of tissue 2-deoxy-D-[1-14C]-glucose-6-phosphate (2-
DG-6-P) content, tissue samples were homogenized and the
supernatants were loaded to an ion-exchange column to separate
2-DG-6-P from 2-deoxy-D-[1-14C]-glucose.
Results
Clodronate liposomes reduce macrophage content in
visceral adipose tissue of DIO mice
To determine whether reduced visceral adipose macrophage
content will be associated with a beneficial effect on improving
insulin resistance in diet-induced obese mice, a chemical approach
was used to deplete macrophages. To ablate adipose tissue
macrophages, clodronate liposomes or PBS liposomes were
injected twice into peritoneal cavities of lean or diet-induced
obese mice with a three-day interval. Adipose tissue was harvested
six days post the first injection for histological studies by
performing immunohistochemistry with an anti-F4/80 antibody
and for real-time PCR analysis for M1 and M2 macrophage
marker genes. As shown in figure 1A–B, F4/80 positive cells are
significantly decreased in adipose tissue from DIO mice treated
with clodronate liposomes compared to control DIO mice injected
with PBS liposomes. CD11c is a commonly accepted M1 marker
gene although its expression is not exclusively restricted to
macrophages. Expression levels of CD11c are decreased in
visceral adipose depots (mesenteric, epididymal and peri-nephric)
but not in subcutaneous adipose tissue (Figure 1C and figure S1A),
indicating that peritoneal injection of clodronate liposomes
selectively targeting visceral adipose depots without affecting
subcutaneous fat. Expression levels of Mgl2, a M2 macrophage
marker gene, are also reduced (Figure 1C and figure S1A). These
data suggest that clodronate liposomes are non-selective regarding
macrophage subtypes. Lean mice injected with clodronate
liposomes also have reduced M1 and M2 macrophage content
in visceral adipose depots (Figure S1B). The lean mice used in our
study are age-matched controls for DIO mice and they are over
twenty-four weeks old. Interestingly, adipose tissue of these lean
mice has more proinflammatory macrophages compared to that of
younger lean mice (Figure S2).
Reduced visceral adipose macrophage content is
associated with mildly improved systemic insulin
sensitivity
Injection of clodronate liposomes did not affect body weight of
either lean or DIO mice under fed or fasted conditions (Figure 2).
Postprandial or fasting blood glucose levels were not significantly
altered in lean mice treated with clodronate liposomes vs. lean mice
injected with PBS clodronate liposomes (Figure 2A). Postprandial
plasma insulin levels in lean mice were not significantly altered
either (Figure 2A). Postprandial and fasting blood glucose levels
were significantly reduced in DIO mice treated with clodronate
liposomes vs. control DIO mice treated with PBS liposomes
(Figure 2B). Plasma insulin levels were also significantly reduced in
DIO mice treated with clodronate liposomes compared to control
DIO mice administered with PBS liposomes (Figure 2B). To test
whether reduced visceral adipose macrophage content is associated
with improved glycemic control, glucose and insulin tolerance tests
were performed in both lean and DIOmice. Injection of clodronate
liposomes mildly improved responses to glucose and insulin
challenges in both lean and DIO mice (Figure 3).
Clodronate liposomes improve hepatosteatosis in DIO
mice
Dissection of mice revealed significant reduction of weights in
epididymal, mesenteric and peri-nephric adipose tissue in lean
Macrophage and Insulin Sensitivity
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mice injected with clodronate liposomes (Figure 4A). Significant
reduction of weights in peri-nephric fat depot was observed in
DIO mice injected with clodronate liposomes (Figure 4A). Liver
weights were also significantly decreased in DIO mice injected
with clodronate liposomes under fasted condition and trended
lower under fed condition (Figure 4B). The reduction of liver
weights is most likely due to decrease in triglyceride content
(Figure 4B). Diet-induced obesity is associated with hepatostea-
tosis. To determine whether reduction in hepatic triglyceride
content alleviated hepatotseatosis, histology studies were per-
formed with livers from DIO mice. As shown in Figure 4C,
massive amounts of lipid droplets were observed in the livers of
DIO mice treated with PBS liposomes but were barely detectable
in the livers of DIO mice treated with clodronate liposomes,
indicating the absence of steatosis. Histology and real-time PCR
studies showed depletion of macrophages in the livers of DIO mice
treated with clodronate liposomes (Figure 5A–B). A hyperinsulin-
emic-euglycemic clamp study revealed significantly increased
percent suppression of hepatic glucose output, suggesting that
the ability of insulin on repressing glucose production in the liver is
enhanced in DIO mice treated with clodronate liposomes
compared to control DIO mice treated with PBS liposomes
(Figure 5C). Glucose uptake in muscle and adipose tissue was not
significantly altered in DIO mice treated with clodronate
Figure 1. Effect of clodronate liposomes on macrophage depletion in fat of DIO mice. A. Histology images of adipose tissues from DIO
mice. Mesenteric, epididymal and peri-renal fat pads from DIO mice treated with either PBS liposomes (PBS) or clodronate liposomes (Clod) by
intraperitoneal injection were fixed, embedded, sectioned and stained with anti-F4/80 antibody (for mesenteric and epididymal fat pads, n = 9–13 per
group; for peri-nephricl fat pads, n = 4 per group). Pictures were taken under 10 fold magnification. B. Quantification of adipose macrophages from
DIO mice treated with PBS or clodronate liposomes. C. Expression of CD11c and Mgl2 in adipose tissues of DIO mice treated with either PBS
liposomes or clodronate liposomes by intraperitoneal injection (n = 7 per group). * P,0.05, PBS liposomes treated vs. clodronate liposomes treated.
In epididymal fat, the P value for CD11c between PBS and clod is 0.086.
doi:10.1371/journal.pone.0024358.g001
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liposomes (Figure 5C). It has been reported that depletion of
macrophages in visceral adipose tissue in lean mice by clodronate
liposomes increases lipolysis and leads to elevated circulating FFA
levels [33]. Increased FFA levels are known to be detrimental to
systemic insulin sensitivity. Elevated plasma FFA levels are also
observed in our DIO mice treated with clodronate liposomes (data
not shown), suggesting that the beneficial phenotype of adipose
macrophage reduction on improving systemic insulin sensitivity
could be attenuated by increased lipolysis.
Clodronate liposomes treatment affects profiles of
cytokine and adipokine in circulation, adipocytes and
stromal vascular cells
To explore the potential mechanism of improved insulin
sensitivity by clodronate liposomes, expression levels of cytokine
and adipokine were profiled in plasma, isolated primary
adipocytes, and stromal vascular cells using ELISA. Circulating
levels of adiponectin were significantly increased and leptin were
significantly decreased in DIO mice injected with clodronate
Figure 2. Body weight, blood glucose and plasma insulin levels in mice treated with clodronate liposomes or PBS liposomes.
A. Body weight, blood glucose and plasma insulin levels of lean mice (n = 4–10 per group) 6–7 days post first injection. B. Body weight, blood
glucose and plasma insulin levels of DIO mice (for BW and blood glucose measurement, n = 12–14 per group for fed condition; n = 7 per group for
fasted condition; for insulin measurement, n = 5 per group for both fed and fasted conditions) 6–7 days post first injection. * P,0.05 clodronate
liposomes treated vs. PBS liposome treated.
doi:10.1371/journal.pone.0024358.g002
Figure 3. Glucose and insulin tolerance tests in mice treated with clodronate liposomes or PBS liposomes. A. Glucose and insulin
tolerance tests in lean mice (n = 4–10 per group). B. Glucose and insulin tolerance tests in DIO mice (n = 7 per group). * P,0.05 clodronate liposomes
treated vs. PBS liposome treated.
doi:10.1371/journal.pone.0024358.g003
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Figure 4. Tissue weights, TAG content and histology. A. Weights of adipose tissue. Epididymal, mesenteric and peri-nephric fat pads were
harvested from lean or DIO mice injected with PBS liposomes or clodronate lipiosomes (For fed DIO mice, n = 6–7 per group; fasted DIO mice, n = 7
per group; lean mice, n = 3–5). B. Weights and triglyceride (TAG) contents of the livers from mice as described in A. C. Histology of the livers from
mice as described in A. Liver section slides were stained with hematoxylin and eosin. Pictures were taken under 40 fold magnification. * P,0.05
clodronate liposomes treated vs. PBS liposomes treated.
doi:10.1371/journal.pone.0024358.g004
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liposomes compared to control DIO mice treated with PBS
liposomes (Figure 6A). Further analysis indicates that the
functional high molecular weight form of adiponectin is also
significantly increased (Figure 6A). Clodronate liposomes signifi-
cantly reduced circulating levels of TNFa under fasting condition
(Figure 6A) but surprisingly increased circulating levels of IL-6
(data not shown). Expression levels of adiponectin were also
increased in isolated primary adipocytes harvested from epididy-
mal and mesenteric fat depots of DIO mice injected with
clodronate liposomes (Figure 6B). Leptin contents were not altered
in adipocytes from epididymal fat depot but were significantly
reduced in adipocytes from mesenteric fat depot of DIO mice
treated with clodronate liposomes (Figure 6B). No change of IL-6
and TNFa content in adipocytes was observed in either fat depot
(Figure 6B). In the stromal vascular fraction isolated from
epididymal depot of DIO mice injected with clodronate liposomes,
no change of IL-6 was observed and TNFa expression was
significantly reduced (Figure 6C). Expression levels of TNFa were
also significantly decreased in the liver of DIO mice treated with
clodronate liposomes (Figure S3). The dramatic decrease of TNFa
levels in both stromal cells of adipose tissue and livers of DIO mice
can potentially contribute to lowered fasting TNFa levels in
circulation.
Macrophage-adipocyte co-culture reduces adiponectin
expression
Adipocyte is an important source of adiponectin. To investigate
the mechanism of increased adiponectin expression upon injection
of clodronate liposomes, we co-cultured 3T3-L1 murine adipo-
cytes and non-stimulated Raw264.7 macrophage line, the latter
produces a large amount of TNFa under b asal condition. We also
treated 3T3-L1 adipocytes with conditioned media derived from
Raw264.7 macrophages. The expression level of adiponectin in
cultured adipocytes was significantly reduced by co-culture with
macrophages or upon exposure to conditioned media from
macrophages (Figure 7), suggesting that macrophage secreted
factors, possibly TNFa, are responsible for repressing adiponectin
production. Increased adiponectin levels in DIO mice injected
with clodronate liposomes are most likely due to adipose
macrophage depletion.
Discussion
Macrophage infiltration, accumulation and activation in
adipose tissue of obese animals have been considered to play an
important role in the development of obesity-related insulin
resistance and type 2 diabetes. Visceral adipose tissue is the fat
depot correlated with obesity-related metabolic syndrome and
reduction of macrophage content in visceral adipose tissue may be
beneficial for improving metabolic syndrome in obese animals.
Despite the fact that a genetic approach was used previously to
deplete CD11c positive macrophages in adipose tissue and
improved systemic insulin sensitivity was observed [22], this
approach theoretically also eliminates macrophages in subcutane-
ous adipose tissue and any tissue that contains macrophages. In
addition, this approach is also expected to deplete non-
macrophages [26]. In our study, we used a chemical reagent to
locally ablate macrophages in visceral adipose tissue. Injection of
clodronate liposomes into peritoneal cavity of mice successfully
reduced macrophage contents in fat depots located within
peritoneal cavity, particularly effective in mesenteric adipose
tissue. Due to the fact that clodronate liposomes can not penetrate
vascular barriers, macrophage content in subcutaneous adipose
tissue is not altered. This approach mildly improved glucose and
insulin tolerance in both lean and diet induced obese mice without
affecting body weight. These results support the hypothesis that
visceral adipose macrophage accumulation at least partially
contributes to the development of obesity-related insulin resistance
Figure 5. Effects of clodronate liposomes on liver. A. Deletion of kupffer cells in the liver of DIO mice by clodronate liposomes. Livers from DIO
mice treated with either PBS liposomes (PBS) or clodronate liposomes (Clod) by intraperitoneal injection were fixed, embedded, sectioned and
stained with anti-F4/80 antibody (n = 4 Per group). Pictures were taken under 60 fold magnification. B. Expression of F4/80 mRNA in the livers of DIO
mice treated with either PBS liposomes or clodronate liposomes (n = 6–7 Per group). C. Hyperinsulinemic-euglycemic clamp study in DIOmice treated
with clodronate liposomes or PBS liposomes (n = 4 per group). Percent suppression of hepatic glucose production (HGP), muscle and adipose glucose
uptake were compared between DIO mice injected with clodronate liposomes or PBS liposomes. * P,0.05 clodronate liposomes treated vs. PBS
liposomes treated. HGP, hepatic glucose production.
doi:10.1371/journal.pone.0024358.g005
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Figure 6. Effect of macrophage ablation on expression profiles of adipokine and cytokine. A. Expression levels of adipokine and cytokine
in plasma from DIO mice ip injected with clodronate liposomes or PBS liposomes (Fed, n = 6–7 each group; fasted, n = 7 each group). B. Expression
levels of adipokine and cytokine in isolated adipocytes from epididymal and mesenteric fat depots from DIO mice ip injected with clodronate
liposomes or PBS liposomes. C. Expression levels of cytokine in stromal vascular cells isolated from epididymal fat depot of DIO mice ip injected with
clodronate liposomes or PBS liposomes. * P,0.05, clodronate liposomes treated vs. PBS liposomes treated.
doi:10.1371/journal.pone.0024358.g006
Macrophage and Insulin Sensitivity
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and hyperglycemia. The beneficial phenotype is mild, which could
be due to undesired complication of M2 macrophage depletion
and elevated circulating FFA levels, both are detrimental to
systemic insulin sensitivity.
Livers are also readily accessible by clodronate liposomes
injected into peritoneal cavity. Three studies reported deletion of
liver kupffer cells by clodronate liposomes in diet-induced mice
[29–31]. These studies applied a much lower (or an unspecified)
dose of clodronate liposomes. The authors did not observe a
beneficial effect on systemic glucose homeostasis and neither did
they report any effect on adipose tissue macrophage ablation.
Despite successful deletion of kupffer cells in all studies,
contradictory conclusions regarding the role of kupffer cells in
obesity-related hepatosteatosis and hepatic insulin resistance are
made. In our study, dramatic reduction of triglyceride content was
observed in the livers of DIO mice treated with clodronate
liposomes which essentially eliminated obesity-associated hepatos-
teatosis. We previously reported that obesity-induced inflamma-
tion was specifically located to adipose tissue, not liver or other
organs although there are residential macrophages in the liver [6].
Therefore, we speculate that improved hepatosteatosis may be a
secondary effect of macrophage reduction in visceral adipose
tissue. Indeed, depletion of kupffer cells in DIO mice by
intravenous injection of clodronate liposomes, which did not
affect visceral adipose macrophage content, did not alter liver
triglyceride content, had no improvement on hepatosteatosis or
hyperglycemia (data not shown). Therefore macrophage reduction
in other tissue/organ other than liver itself may account for
attenuated hepatosteatosis and improved glucose/insulin toler-
ance. One possibility could be that alteration of macrophage
content in visceral adipose tissue may cause changes of secreted
factors that can potentially impact liver.
Expression profiles of adipokines and cytokines in diet induced
mice were profoundly altered by administration of clodronate
liposomes. Adiponection is an anti-inflammatory and insulin
sensitizing hormone [34]. Circulating levels of adiponectin are
negatively correlated with body fat and are decreased in obese and
diabetic patients. Treatment with clodronate liposomes increased
adiponectin levels in both adipocytes and circulation. It is possible
that elevated circulating levels of adiponectin contributed to the
Figure 7. 3T3-L1 adipocytes and Raw264.7 macrophage co-culture experiment. A. Expression of TNFa and adiponectin in L1 adipocytes
(Adi) and L1+macrophages (Mw). Macrophages were seeded on top of fully differentiated adipocytes for two days, then co-cultured cells were
incubated in serum-free medium overnight prior to RNA extraction. B. Expression of TNFa and adiponectin in L1 adipocytes treated with normal
medium or conditioned medium from macrophages (Sup). C. Expression of TNFa and adiponectin in conditioned media from adipocytes (Adi),
adipocyte and macrophage co-culture (Adi+ Mw), adipocyte twenty four hours after removal of conditioned macrophage supernatant, or
macrophage supernatant. *P,0.05 compared to adipocyte control. Data shown are representative experiment out of three independent experiments
performed.
doi:10.1371/journal.pone.0024358.g007
Macrophage and Insulin Sensitivity
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24358
improvement of hepatosteatosis in DIO mice treated with
clodronate liposomes. It has been reported that adiponectin
deficient mice develop hepatosteatosis whereas elevation of
adiponectin levels in circulation through pharmacological and
genetic approaches protect mice from developing obesity-related
hepatosteatosis [35,36]. Adiponectin is also considered a good
marker for predicting severity of non-alcoholic fatty liver disease
and recent therapeutic approaches have been focused on indirectly
increasing adiponectin levels [37]. The potential mechanisms by
which adiponectin improves hepatosteatosis include involvement
of multiple pathways such as activation of SIRT1 and AMP-
activated protein kinase, promotion of fatty acid oxidation in the
liver, and suppression of toll-like receptor 4 signaling [38,39].
Future studies will be necessary to explore whether adiponectin
alleviates hepatosteatosis in DIO mice injected with clodronate
liposomes via aforementioned pathways. Leptin, on the other
hand, is a pro-inflammatory hormone that is positively correlated
with body fat and is elevated in circulation of obese and diabetic
patients [34]. Leptin levels in circulation and mesenteric
adipocytes were decreased by treatment of clodronate liposomes.
TNFa expression levels were decreased in stromal cells of adipose
tissue and liver of DIO mice injected with clodronate liposomes,
which may contribute to lowered circulating TNFa levels under
fasting condition. Decreased TNFa level possibly contributes to
increased adiponectin level as substantial evidence in literature
demonstrate that TNFa inhibits adiponectin expression [40–44].
Our study also indicates that TNFa-producing macrophages can
decrease adiponectin expression and release in 3T3-L1 adipocytes
during co-culture. Alteration of circulating adipokine and cytokine
levels provides a possible explanation that locally administered
clodronate liposomes were capable of mildly improving systemic
insulin sensitivity. We do not exclude the possibilities that
macrophage reduction in other organs located in the peritoneal
cavity (such as spleen, intestine etc) also contribute to improved
systemic insulin sensitivity. In summary, it is feasible to improve
metabolic profile of DIO mice using the chemical approach of
macrophage ablation. Chemical reagents selectively ablate M1
macrophages may have a bigger beneficial effect.
Supporting Information
Figure S1 Macrophage contents in adipose tissue from
DIO and lean mice injected with clodronate liposomes.
A. Expression levels of CD11c and Mgl2 in subcutaneous adipose
tissue of DIO mice treated with clodronate or PBS liposomes by
intraperitoneal injection (n = 5 per group). B. Expression levels of
CD11c and Mgl2 in adipose tissues from lean mice treated with
clodronate or PBS liposomes by intraperitoneal injection (n = 4–5
per group). * P,0.05, PBS vs. clodronate liposomes. Clod,
clodronate liposomes.
(TIF)
Figure S2 Expression levels of CD11c in epididymal
adipose tissue of five and twenty-five week-old
leanC57BL/6 male mice (n=5–7). * P,0.05, 5 week vs. 25
week old mice.
(TIF)
Figure S3 TNFa expression in liver from DIO mice
treated with PBS or clodronate liposomes (n=6–7 per
group). Livers from DIO mice treated with PBS liposomes (PBS)
or clodronate liposomes (Clod) by IP injection were harvested and
used for RNA preparation. TNFa expression was determined by
real-time PCR analysis. *P,0.05, PBS vs. clodronate liposomes.
(TIF)
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